Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F21%3A00074824" target="_blank" >RIV/65269705:_____/21:00074824 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00209805:_____/21:00078873 RIV/00216224:14110/21:00124279

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0145212621001855?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0145212621001855?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.leukres.2021.106684" target="_blank" >10.1016/j.leukres.2021.106684</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion

Popis výsledku v původním jazyce

The in vivo rituximab effects in B cell malignancies are only partially understood. Here we analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n = 80) the inter-patient variability in CLL cell count reduction within the first 24 h of rituximab administration in vivo, and a phenomenon of blood repopulation by malignant cells after anti-CD20 antibody therapy. Larger CLL cell elimination after rituximab infusion was associated with lower pre-therapy CLL cell counts, higher CD20 levels, and the non-exhausted capacity of complement dependent cytotoxicity (CDC). The absolute amount of cell-surface CD20 molecules (CD20 density x CLL lymphocytosis) was a predictor for complement exhaustion during therapy. We also describe that a highly variable decrease in CLL cell counts at 5 h (88 %-2%) following rituximab infusion is accompanied in most patients by peripheral blood repopulation with CLL cells at 24 h, and in similar to 20 % of patients, this resulted in CLL counts higher than before therapy. We provide evidence that CLL cells recrudescence is linked with i) CDC exhaustion, which leads to the formation of an insufficient amount of membrane attack complexes, likely resulting in temporary retention of surviving rituximab-opsonized cells by the mononuclear-phagocyte system (followed by their release back to blood), and ii) CLL cells regression from immune niches (CXCR4(dim)CD5(bright) intraclonal subpopulation). Patients with major peripheral blood CLL cell repopulation exhibited a longer time to-progression after chemoimmunotherapy compared to patients with lower or no repopulation, suggesting chemotherapy vulnerability of CLL cells that repopulate the blood.

Název v anglickém jazyce

Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion

Popis výsledku anglicky

The in vivo rituximab effects in B cell malignancies are only partially understood. Here we analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n = 80) the inter-patient variability in CLL cell count reduction within the first 24 h of rituximab administration in vivo, and a phenomenon of blood repopulation by malignant cells after anti-CD20 antibody therapy. Larger CLL cell elimination after rituximab infusion was associated with lower pre-therapy CLL cell counts, higher CD20 levels, and the non-exhausted capacity of complement dependent cytotoxicity (CDC). The absolute amount of cell-surface CD20 molecules (CD20 density x CLL lymphocytosis) was a predictor for complement exhaustion during therapy. We also describe that a highly variable decrease in CLL cell counts at 5 h (88 %-2%) following rituximab infusion is accompanied in most patients by peripheral blood repopulation with CLL cells at 24 h, and in similar to 20 % of patients, this resulted in CLL counts higher than before therapy. We provide evidence that CLL cells recrudescence is linked with i) CDC exhaustion, which leads to the formation of an insufficient amount of membrane attack complexes, likely resulting in temporary retention of surviving rituximab-opsonized cells by the mononuclear-phagocyte system (followed by their release back to blood), and ii) CLL cells regression from immune niches (CXCR4(dim)CD5(bright) intraclonal subpopulation). Patients with major peripheral blood CLL cell repopulation exhibited a longer time to-progression after chemoimmunotherapy compared to patients with lower or no repopulation, suggesting chemotherapy vulnerability of CLL cells that repopulate the blood.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/GA20-02566S" target="_blank" >GA20-02566S: FOXO1-GAB1 SIGNALIZACE A MOLEKULÁRNÍ DRÁHY ŘÍDÍCI RE-CIRKULACI LEUKEMICKÝCH B BUNĚK DO IMUNITNÍCH NICHE: TERAPEUTICKÉ IMPLIKACE</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia Research

ISSN

0145-2126

e-ISSN

—

Svazek periodika

111

Číslo periodika v rámci svazku

DEC

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

106684

Kód UT WoS článku

000703570900003

EID výsledku v databázi Scopus

2-s2.0-85113289606